HIV-1 vaccine design:   harnessing diverse lymphocytes to conquer a diverse pathogen.
In the fall of 2007, the HIV-1 research field received news that their front-runner vaccine was not protective. In response to this disappointment, scientists are now reviewing the intricacies of the immune response toward HIV-1 to develop new and better strategies for vaccine development. Decades ago, researchers recognized the impressive amino acid and carbohydrate diversity of HIV-1, and the associated obstacles to vaccine development. At first glance, the diversity and other unique features of HIV-1 may seem insurmountable, but attention to vaccine successes in other fields serves to renew optimism. The newly-licensed rotavirus and papillomavirus cocktail vaccines remind scientists that diverse pathogens can be conquered and that the chronic nature of a virus infection need not thwart successful vaccine design. Here we describe current efforts to gain insights from other vaccine fields and to adopt a cocktail vaccine approach for the prevention of HIV-1 infections in humans.
Surman
Sherri L
SL
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Sealy
Robert
R
Jones
Bart G
BG
Hurwitz
Julia L
JL
D016915:AIDS Vaccines / Q000276:immunology*; D014644:Genetic Variation; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D053918:Papillomavirus Vaccines / Q000276:immunology; D022243:Rotavirus Vaccines / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
D016915:AIDS Vaccines; D053918:Papillomavirus Vaccines; D022243:Rotavirus Vaccines
J Immunol. 2003 Nov 15;171(10):4969-73
14607890
J Virol. 1996 Jul;70(7):4361-9
8676459
Lancet. 2008 Nov 29;372(9653):1894-1905
19012957
J Infect Dis. 2007 Sep 15;196(6):895-9
17703421
J Infect Dis. 2003 Aug 1;188(3):397-405
12870121
J Acquir Immune Defic Syndr (1988). 1994 Mar;7(3):211-9
8106963
J Gen Virol. 1996 Dec;77 ( Pt 12):2969-81
9000087
Vaccine. 2007 May 16;25(20):4085-92
17391815
J Virol. 2005 Mar;79(5):2956-63
15709015
AIDS Res Hum Retroviruses. 1998 May 20;14(8):717-9
9618085
Science. 2004 Sep 10;305(5690):1545-7
15361591
Clin Diagn Lab Immunol. 2003 Sep;10(5):744-50
12965898
J Virol. 1996 Apr;70(4):2627-31
8642697
J Gen Virol. 1997 Oct;78 ( Pt 10):2529-39
9349474
Lancet. 2007 Jul 7;370(9581):94-101
17617277
J Biol Chem. 1999 Jan 22;274(4):1905-13
9890944
J Virol. 2003 Dec;77(23):12764-72
14610198
AIDS Res Hum Retroviruses. 2004 Sep;20(9):1026-31
15585092
Pediatr Infect Dis J. 2006 Jul;25(7):577-83
16804425
J Infect Dis. 1999 Sep;180(3):673-84
10438354
J Immunol Methods. 2006 Jan 20;308(1-2):53-67
16343526
Science. 2005 Jun 24;308(5730):1906-8
15860590
J Virol. 2006 Jun;80(12):6177-81
16731957
Vaccine. 2004 Mar 12;22(9-10):1206-13
15003649
Science. 1992 Jan 24;255(5043):456-9
1531159
Pediatr Res. 2007 Nov;62(5):527
18049369
J Immunol. 2003 Oct 15;171(8):4140-8
14530336
J Virol. 2005 Feb;79(4):2042-9
15681406
J Immunol. 2008 Feb 15;180(4):2174-86
18250424
Virology. 1997 Aug 4;234(2):328-39
9268165
Mol Ther. 2007 Sep;15(9):1724-33
17579577
J Virol. 1999 Oct;73(10):8356-63
10482586
Virology. 2008 Jun 5;375(2):315-20
18367229
Vaccine. 2005 Nov 16;23(46-47):5306-20
16095768
Nature. 2007 Sep 27;449(7161):390
17898737
J Virol. 2000 Nov;74(22):10670-80
11044111
Nature. 1990 Jun 14;345(6276):622-5
2190095
Curr Drug Targets Infect Disord. 2005 Jun;5(2):143-56
15975020
Science. 1988 Nov 25;242(4882):1171-3
2460925
J Virol. 2006 Sep;80(18):9217-25
16940533
Virology. 2006 May 10;348(2):341-53
16460776
Science. 2008 Jul 25;321(5888):530-2
18653883
Vaccine. 2003 Oct 1;21(27-30):4243-9
14505905
Vaccine. 1998 Nov;16(19):1803-11
9795384
J Infect Dis. 1997 Aug;176(2):384-97
9237703
Virology. 2002 Oct 10;302(1):44-57
12429515
Virology. 1997 Mar 3;229(1):143-54
9123856